Role of CXCL12 and CXCR4 in normal cerebellar development and medulloblastoma
Patricia Midori Murobushi Ozawa
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorCarolina Batista Ariza
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorCintya Mayumi Ishibashi
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorThiago Cezar Fujita
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorBruna Karina Banin-Hirata
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorJulie Massayo Maeda Oda
Federal University of Mato Grosso do Sul, Três Lagoas, Brazil
Search for more papers by this authorCorresponding Author
Maria Angelica Ehara Watanabe
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Correspondence to: Maria Angelica Ehara Watanabe, Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil, E-mail: [email protected]Search for more papers by this authorPatricia Midori Murobushi Ozawa
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorCarolina Batista Ariza
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorCintya Mayumi Ishibashi
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorThiago Cezar Fujita
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorBruna Karina Banin-Hirata
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Search for more papers by this authorJulie Massayo Maeda Oda
Federal University of Mato Grosso do Sul, Três Lagoas, Brazil
Search for more papers by this authorCorresponding Author
Maria Angelica Ehara Watanabe
Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil
Correspondence to: Maria Angelica Ehara Watanabe, Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Brazil, E-mail: [email protected]Search for more papers by this authorGrant sponsor: The author Patricia Midori Murobushi Ozawa received Grad Student's Fellowship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). The authors would like to acknowledge Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação Araucária do Paraná, Secretaria da Ciência, Tecnologia e Ensino Superior (SETI), Fundo Estadual para a Infância e Adolescência (FIA/PR) e Secretaria da Família e Desenvolvimento Social (SEDS) and Pró-Reitoria de Pesquisa e Pós-graduação da Universidade Estadual de Londrina (PROPPG-UEL).
Abstract
Chemokines and its receptors have significant impact on physiological and pathological processes and studies concerning their association with tumor biology are subject of great interest in scientific community. CXCL12/CXCR4 axis has been widely studied due to its significant role in tumor microenvironment, but it is also important to development and maintenance of tissues and organs, for example, in the brain and cerebellum. Studies have demonstrated that CXCL12 and CXCR4 are required for normal cerebellar development and that dysfunction in this pathway may be involved with medulloblastoma pathogenesis. In this context, a new molecular subgroup has been suggested based on the importance of the association between CXCR4 overexpression and sonic hedgehog subgroup. Treatment using CXCR4 antagonists showed significant results, evidencing the important role and possible therapeutic capacity of CXCR4 in MB. This review summarizes studies on MB cell biology, focusing on a chemokine-receptor axis, CXCL12/CXCR4, that may have implications for treatment strategies once it can improve life expectancy and reduce neurocognitive sequelae of patients with this neoplasia.
References
- 1Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650–9.
- 2Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423–37.
- 3Ronnov-Jessen L, Petersen OW, Koteliansky VE, et al. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995; 95: 859–73.
- 4Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540–50.
- 5Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003; 63: 1969–74.
- 6Balkwill F. Chemokine biology in cancer. Semin Immunol 2003; 15: 49–55.
- 7Yu L, Cecil J, Peng SB, et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 2006; 374: 174–9.
- 8Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–6.
- 9Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003; 63: 3833–9.
- 10Arscott WT, LaBauve AE, May V, et al. Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene 2009; 28: 479–91.
- 11Airoldi I, Raffaghello L, Piovan E, et al. CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications. Clin Cancer Res 2006; 12: 77–82.
- 12Schuller U, Koch A, Hartmann W, et al. Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas. Int J Cancer 2005; 117: 82–9.
- 13Zhao Q, Kho A, Kenney AM, et al. Identification of genes expressed with temporal-spatial restriction to developing cerebellar neuron precursors by a functional genomic approach. Proc Natl Acad Sci USA 2002; 99: 5704–9.
- 14Klein RS, Rubin JB, Gibson HD, et al. SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development 2001; 128: 1971–81.
- 15Sengupta R, Dubuc A, Ward S, et al. CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res 2012; 72: 122–32.
- 16Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003; 100: 13513–8.
- 17Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008; 14: 135–45.
- 18Bian XW, Yang SX, Chen JH, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007; 61: 570–8; discussion 8–9.
- 19Calatozzolo C, Maderna E, Pollo B, et al. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 2006; 5: 827–32.
- 20Barbieri F, Bajetto A, Stumm R, et al. Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res 2008; 14: 5022–32.
- 21Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008; 48: 171–97.
- 22Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121–7.
- 23Fischer L, Korfel A, Pfeiffer S, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 2009; 15: 5968–73.
- 24Kryczek I, Wei S, Keller E, et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007; 292: C987–95.
- 25Petrai I, Rombouts K, Lasagni L, et al. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 2008; 40: 1764–74.
- 26Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927–31.
- 27Bartolome RA, Galvez BG, Longo N, et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004; 64: 2534–43.
- 28Reiland J, Furcht LT, McCarthy JB. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999; 41: 78–88.
10.1002/(SICI)1097-0045(19991001)41:2<78::AID-PROS2>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- 29Ivanoff J, Talme T, Sundqvist KG. The role of chemokines and extracellular matrix components in the migration of T lymphocytes into three-dimensional substrata. Immunology 2005; 114: 53–62.
- 30Krathwohl MD, Kaiser JL. Chemokines promote quiescence and survival of human neural progenitor cells. Stem Cells 2004; 22: 109–18.
- 31Hattermann K, Ludwig A, Gieselmann V, et al. The chemokine CXCL16 induces migration and invasion of glial precursor cells via its receptor CXCR6. Mol Cell Neurosci 2008; 39: 133–41.
- 32Reiss K, Mentlein R, Sievers J, et al. Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer. Neuroscience 2002; 115: 295–305.
- 33Andjelkovic AV, Pachter JS. Characterization of binding sites for chemokines MCP-1 and MIP-1alpha on human brain microvessels. J Neurochem 2000; 75: 1898–906.
- 34van der Meer P, Ulrich AM, Gonzalez-Scarano F, et al. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp Mol Pathol 2000; 69: 192–201.
- 35Stumm RK, Rummel J, Junker V, et al. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci 2002; 22: 5865–78.
- 36Rostene W, Dansereau MA, Godefroy D, et al. Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system. J Neurochem 2011; 118: 680–94.
- 37Adler MW, Rogers TJ. Are chemokines the third major system in the brain? J Leukoc Biol 2005; 78: 1204–9.
- 38Secchiero P, Celeghini C, Cutroneo G, et al. Differential effects of stromal derived factor-1 alpha (SDF-1 alpha) on early and late stages of human megakaryocytic development. Anat Rec 2000; 260: 141–7.
- 39Wright LM, Maloney W, Yu X, et al. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 2005; 36: 840–53.
- 40Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382: 833–5.
- 41Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872–7.
- 42Doitsidou M, Reichman-Fried M, Stebler J, et al. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell 2002; 111: 647–59.
- 43Hatten ME, Heintz N. Mechanisms of neural patterning and specification in the developing cerebellum. Annu Rev Neurosci 1995; 18: 385–408.
- 44Wingate RJ. The rhombic lip and early cerebellar development. Curr Opin Neurobiol 2001; 11: 82–8.
- 45Zhu Y, Yu T, Zhang XC, et al. Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat Neurosci 2002; 5: 719–20.
- 46Bagri A, Gurney T, He X, et al. The chemokine SDF1 regulates migration of dentate granule cells. Development 2002; 129: 4249–60.
- 47Ohshima Y, Kubo T, Koyama R, et al. Regulation of axonal elongation and pathfinding from the entorhinal cortex to the dentate gyrus in the hippocampus by the chemokine stromal cell-derived factor 1 alpha. J Neurosci 2008; 28: 8344–53.
- 48Takeuchi H, Natsume A, Wakabayashi T, et al. Intravenously transplanted human neural stem cells migrate to the injured spinal cord in adult mice in an SDF-1- and HGF-dependent manner. Neurosci Lett 2007; 426: 69–74.
- 49Filippo TR, Galindo LT, Barnabe GF, et al. CXCL12 N-terminal end is sufficient to induce chemotaxis and proliferation of neural stem/progenitor cells. Stem Cell Res 2013; 11: 913–25.
- 50Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595–9.
- 51Zhu Y, Yu T, Rao Y. Temporal regulation of cerebellar EGL migration through a switch in cellular responsiveness to the meninges. Dev Biol 2004; 267: 153–64.
- 52Dhall G. Medulloblastoma. J Child Neurol 2009; 24: 1418–30.
- 53Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001; 17: 503–11.
- 54Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123: 473–84.
- 55Li KK, Lau KM, Ng HK. Signaling pathway and molecular subgroups of medulloblastoma. Int J Clin Exp Pathol 2013; 6: 1211–22.
- 56Giangasparo F, Bigner SH, Kleinhues PK, et al. Medulloblastoma. In: P CW Kleihues, ed. Pathology and genetics of tumors of the nervous system. Lyon: World Health Organization classification of tumors, 2000. 129–37.
- 57Hatten ME, Roussel MF. Development and cancer of the cerebellum. Trends Neurosci 2011; 34: 134–42.
- 58Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385–428.
- 59Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004; 63: 441–9.
- 60Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000; 89: 395–402.
- 61Yuan L, Zhang H, Liu J, et al. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer 2013; 12: 18.
- 62Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29: 1424–30.
Citing Literature
